Angiopoietin-Like 3 Antibody Therapy in Patients With Suboptimally Controlled Hyperlipidemia

Journal of the American College of Cardiology, Год журнала: 2025, Номер unknown

Опубликована: Март 1, 2025

Язык: Английский

---

Antibodies to watch in 2025

mAbs, Год журнала: 2024, Номер 17(1)

Опубликована: Дек. 22, 2024

The commercial development of antibody therapeutics is a global enterprise involving thousands biopharmaceutical firms and supporting service organizations. To date, their combined efforts have resulted in over 200 marketed pipeline nearly 1,400 investigational product candidates that are undergoing evaluation clinical studies as treatments for wide variety diseases. Here, we discuss key events occurred during 2024 forecast related to the late-stage may occur 2025. In particular, report on 21 granted first approval at least one country or region 2024, including bispecific antibodies tarlatamab (IMDELLTRA®), zanidatamab (Ziihera®), zenocutuzumab (BIZENGRI®), odronextamab (Ordspono®), ivonescimab (依達方®), antibody–drug conjugate (ADC) sacituzumab tirumotecan (佳泰萊®). We also 30 which marketing applications were review by regulatory agency, our last update December 9, ADCs datopotamab deruxtecan, telisotuzumab vedotin, patritumab trastuzumab botidotin, becotatug rezetecan. Of 178 include pipeline, summarize data 18 be submitted end 2025, such bi- multispecific denecimig, sonelokimab, erfonrilimab, anbenitamab. Key trends formats bispecifics ADCs, well clinical-phase transition success rates these formats, reported.

Язык: Английский

---

Targeting PCSK9 beyond the liver: evidence from experimental and clinical studies

Expert Opinion on Therapeutic Targets, Год журнала: 2025, Номер unknown

Опубликована: Март 20, 2025

PCSK9 has been widely studied as a target for lipid-lowering its inhibition increases LDL-R recycling on the surface of hepatocytes, which promotes catabolism LDL particles.PCSK9 can be synthesized in extra-hepatic tissues, including brain, pancreas, heart, and immune cells. This is interest to understand whether effects observed when genetically inhibited by naturally occurring mutations are also recapitulated pharmacology. Genetics studies reported an increased risk developing new-onset diabetes, ectopic adiposity reduced immune-inflammatory responses with deficiency. However, these aspects were not clinical trials data from real world medicine monoclonal antibodies (mAbs) gene silencing approaches targeting PCSK9. It possible that biological adaptations lifelong, case genetic studies, could explain discrepancy obtained testing pharmacological Also, mAbs have use 12 years, thus probably, this time window, reduction circulating up 80-90% does lead changes other than impressive LDL-C CVD events.

Язык: Английский

---

A Phase I Study to Evaluate the Relative Bioavailability, Pharmacodynamics, and Safety of a Single Subcutaneous Injection of Recaticimab at Three Different Sites in Healthy Chinese Subjects

European Journal of Drug Metabolism and Pharmacokinetics, Год журнала: 2025, Номер unknown

Опубликована: Апрель 19, 2025

Язык: Английский

---

Oral PCSK9 Inhibitors: Will They Work?

Current Atherosclerosis Reports, Год журнала: 2025, Номер 27(1)

Опубликована: Апрель 30, 2025

Язык: Английский

---

An evaluation of recaticimab for the treatment of hypercholesterolemia

Expert Opinion on Biological Therapy, Год журнала: 2025, Номер unknown

Опубликована: Май 17, 2025

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, by preventing the degradation of LDL receptors, either through interference in binding PCSK9 to receptors or silencing at a molecular level, have revolutionized lipid-lowering treatment and offer opportunity further improve clinical outcomes for patients with hypercholesterolemia. We discuss role as therapeutic target hypercholesterolemia, describe pharmacodynamics, pharmacokinetics, metabolism recaticimab, report recent trials this 'humanized' IgG1 monoclonal antibody (mAb) against PCSK9. Recaticimab has high affinity that confers prolonged duration action. durably decreases LDL-cholesterol, non-HDL-cholesterol apoB, but can also lower Lp(a). may advantages over current mAbs use terms its long half-life, dosing interval up 12 weeks, potentially cost, however, long-term concerns regarding immunogenicity remain. Longer-term studies variety more diverse patient cohorts will be needed evaluate efficacy, safety, durability recaticimab ascertain best schedule cardiovascular outcome studies.

Язык: Английский

---

A Step Forward for Long-Acting PCSK9 Inhibition

Journal of the American College of Cardiology, Год журнала: 2024, Номер 84(20), С. 2048 - 2050

Опубликована: Окт. 9, 2024

Язык: Английский

---